The Giant-Cell Arteritis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of giant-cell arteritis has seen significant growth recently. It is projected to increase from $1.07 billion in 2024 to $1.12 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%.
The market for giant-cell arteritis is anticipated to expand to $1.36 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%.
Download Your Free Sample of the 2025 Giant-Cell Arteritis Market Report and Uncover Key Trends Now!The drivers in the giant-cell arteritis market are:
• The surge in epidemiological studies related to giant-cell arteritis
• Developments in genetic insights concerning the disease
• The rising incorporation of biologics in treatment strategies
• Advancements in diagnostic techniques and the development of targeted therapies.
The giant-cell arteritis market covered in this report is segmented –
1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin
2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action
3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration
The trends in the giant-cell arteritis market are:
• There is a trend towards advancements in the identification and validation of biomarkers.
• The development of therapies targeting specific molecular pathways is an emerging trend.
• The adoption of advanced imaging techniques is significantly shaping the future of the market.
• The utilization of AI algorithms for predictive analytics is an upcoming trend.
The major players in the giant-cell arteritis market are:
• Pfizer Inc.
North America was the largest region in the giant-cell arteritis market in 2023